77 reports of this reaction
1.5% of all RUFINAMIDE reports
#18 most reported adverse reaction
EPILEPSY is the #18 most commonly reported adverse reaction for RUFINAMIDE, manufactured by Eisai Inc.. There are 77 FDA adverse event reports linking RUFINAMIDE to EPILEPSY. This represents approximately 1.5% of all 5,100 adverse event reports for this drug.
Patients taking RUFINAMIDE who experience epilepsy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPILEPSY is a less commonly reported adverse event for RUFINAMIDE, but still significant enough to appear in the safety profile.
In addition to epilepsy, the following adverse reactions have been reported for RUFINAMIDE:
The following drugs have also been linked to epilepsy in FDA adverse event reports:
EPILEPSY has been reported as an adverse event in 77 FDA reports for RUFINAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPILEPSY accounts for approximately 1.5% of all adverse event reports for RUFINAMIDE, making it a notable side effect.
If you experience epilepsy while taking RUFINAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.